5-HT3 serotonergic receptor mediation of hypoglycemia-induced arginine-vasopressin but not oxytocin secretion in normal men.
The present study was undertaken in order to establish the possible involvement of 5-HT3 serotonergic receptors in the control of basal and/or hypoglycemia-stimulated arginine vasopressin (AVP) and/or oxytocin (OT) secretion. For this purpose, 12 normal men were injected intravenously with a bolus of 4 mg ondansetron, a specific 5-HT3 receptor antagonist, under basal conditions (n = 6) or 30 min before insulin (0.15 IU/kg body weight) administration (n = 6) (insulin tolerance test (ITT)). Control experiments with normal saline instead of ondansetron treatment were performed. Furthermore, on a different occasion, the same subjects were tested in identical experimental conditions with 8 mg ondansetron. Our results showed that the hypoglycemic response to insulin was similar during the ITT and ondansetron plus ITT. Inhibition of 5-HT3 serotonergic receptors with ondansetron (4 or 8 mg) did not modify the basal secretion of AVP and OT and the OT response to insulin-induced hypoglycemia. In contrast, the administration of 4 or 8 mg ondansetron significantly reduced in a similar manner hypoglycemia-induced AVP rise. Mean peak level at 45 min after insulin injection was 2.25 times higher than baseline in the control ITT and 1.5 times higher than basal value in the ondansetron (4 or 8 mg) plus ITT. These data demonstrate that 5-HT3 serotonergic receptors at least partially mediate the AVP response to hypoglycemia, without modifying the simultaneous OT response. On the other hand, 5-HT3 receptors do not appear to be involved in the control of basal posterior pituitary hormone secretions.
Volpi
R
R
Dipartimento di Medicina Interna Università di Parma, Italy.
Chiodera
P
P
Giuliani
N
N
Capretti
L
L
Caffarri
G
G
Magotti
M G
MG
Coiro
V
V
D000328:Adult; D001127:Arginine Vasopressin / Q000378:metabolism*; D006801:Humans; D007003:Hypoglycemia / Q000503:physiopathology*; D007328:Insulin; D007700:Kinetics; D008297:Male; D017294:Ondansetron; D010121:Oxytocin / Q000378:metabolism*; D010919:Placebos; D011985:Receptors, Serotonin / Q000502:physiology*; D012702:Serotonin Antagonists
D007328:Insulin; D010919:Placebos; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D001127:Arginine Vasopressin; D017294:Ondansetron; D010121:Oxytocin